Vertex Signs Gene Editing Partnership with Verve for US$466 M
By Swati Sharan
Pharma Deals Review: Vol 2022 Issue 7 (Table of Contents)
Published: 29 Jul-2022
DOI: 10.3833/pdr.v2022.i7.2709 ISSN: 1756-7874
Section: Licensing
Fulltext:
Abstract
In a bid to broaden its gene editing capabilities, Vertex Pharmaceuticals has entered into a four-year global research collaboration agreement with Verve Therapeutics...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS